Consent to the Distribution of a New Medicine Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Hepatitis B immunoglobulin (Human) 100IU in 16% IgG, 400IU in 16% IgG Injection, solution CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia Hepatitis B Immunoglobulin Ipratropium bromide monohydrate 260.9g/mL equivalent to 250g/mL ipratropium bromide Inhalation, solution Steripak Limited, Astmoor, Runcorn, Cheshire, England Ipratropium Steri-Neb Human Immunoglobulin G 160 mg/mL in 16% IgG Injection, solution CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia Normal Immunoglobulin Anti-D (Rho) immunoglobulin (Human) 250IU in 16% IgG, 625IU in 16% IgG Injection, solution CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia Rh(D) Immunoglobulin Flurbiprofen 8.75 mg Lozenge The Boots Company Plc., Beeston, Nottingham, United Kingdom Strepfen Fexofenadine hydrochloride 60 mg, pseudoephedrine hydrochloride 120 mg Tablet, film coated Hoechst Marion Roussel Inc., Kansas City, Missouri, United States of America Telfast Decongestant Tetanus immunoglobulin (Human) 250IU in 16% IgG Injection, solution CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia Tetanus Immunoglobulin Zoster immunoglobulin (Human) 100IU/mL in 16% IgG Injection, solution CSL Limited, Bioplasma Division, Broadmeadows, Victoria, Australia Zoster Immunoglobulin Dated this 5th day of February 1999. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.